NFXF Webinar Recap In case you don’t have time, or would prefer the information in written form, we are now providing NFXF Webinar recaps. These are summaries of the webinars, using paraphrases rather than [...]
Need a new search?
If you didn't find what you were looking for, try a new search!
Video clip from local news station covering a family who participated in a study that later ended and they want to get their hands on the drug that they called a miracle drug.
Note: Just before I wrote this article, a group of parents that Margaret Mead could have easily been describing when she penned her most famous quote ("Never doubt that a small group of committed people [...]
After the International Meeting for Autism Research in Spain, the news organization Reuters published an article titled “Key trial of Seaside autism drug fails to show benefit.” In order to provide context and help the [...]
Fragile X expert Dr. Randi Hagerman was interviewed by writer and autism advocate Laura Shumaker for an article appearing in SFGATE (sister-site of the San Francisco Chronicle) in January 2013. In the interview, Dr. Hagerman talks about Fragile [...]
Autism Speaks, the world's largest autism advocacy organization, recently released it's Top Ten Autism Research Advances of 2012. Included in this list is Fragile X research, mainly two drug studies of Arbaclofen. This is a [...]
Seaside Therapeutics is studying the science of the brain and working to deliver treatments that improve the underlying causes of developmental disorders like Fragile X syndrome. Right now, Seaside is testing an investigational medicine called STX209 (arbaclofen) for individuals with Fragile X syndrome with social impairment. Thanks to the dedication and efforts of families, one of the clinical trials is almost complete.
The NFXF is pleased to see the media attention surrounding the latest news resulting from clinical trials for Fragile X syndrome treatments. Two members of the NFXF’s Scientific and Clinical Advisory Committee, Dr. Randi Hagerman, the NFXF’s co-founder, and Dr. Elizabeth Berry-Kravis, also a member of the NFXF’s Board of Directors, have been receiving prominent mention. The NFXF has been pleased to be able to assist its corporate partner, Seaside Therapeutics, with recruitment for this trial and others.
Roche and Seaside Therapeutics announced today that they have entered into a collaboration to develop disease modifying treatments for Fragile X syndrome (FXS) and autism spectrum disorders (ASD), both neurodevelopmental disorders